TOP HEADLINES

Featured Story

China green-lights domestic Ebola shot for clinical trials

China has approved a locally developed Ebola vaccine from its Academy of Military Medical Sciences for clinical trials, state news agency Xinhua said Thursday.

GSK shingles candidate hits its mark in hefty Phase III study

More than four years ago, GlaxoSmithKline began a Phase III study of a shingles candidate it hoped would eventually mount a challenge to Merck's Zostavax. Now, that candidate is one step closer after hitting its primary endpoint in that trial.

Finnish scientists ID link between GSK's swine flu vaccine and narcolepsy

A team from Finland has for the first time confirmed a link between GlaxoSmithKline's swine flu vaccine, Pandemrix, and narcolepsy.

Study: Universal dengue vaccine may be possible thanks to antibody discovery

So far, Sanofi's dengue candidate, the furthest along in the clinic, has struggled to ward off all four dengue viruses. But now, researchers have discovered new antibodies that could lead to a vaccine that does just that.

Baxter backs away from vaccines with Vero tech sale to Nanotherapeutics

Baxter, prepping for a biopharma spinoff, has already revealed that vaccines won't figure into its plans going forward. And Monday, it took it second step to exit the space with a sale of its Vero technology and related assets.

MORE NEWS

From Our Sister Sites

FierceMarkets Network
  • FierceBiotech
  • FierceBiotechIT
  • FierceBiotechResearch
  • FierceDrugDelivery
  • FierceMedicalDevices
  • FierceVaccines
  • FiercePharma
  • FiercePharmaManufacturing
  • FierceCRO
  • FierceDiagnostics
  • FiercePharmaMarketing
  • FierceAnimalHealth
  • More Fierce Network sites
FierceBiotech
With Roche out the door, Chiasma is raising $56M to go it alone

In early 2013, Roche signed a $595 million deal with Israel's Chiasma with eyes on its promising treatment for the hormone disorder acromegaly. But the Swiss drugmaker got cold feet over the summer, and now Chiasma is picking up the pieces, raising cash in hopes of submitting its drug to regulators this year.

FierceDiagnostics
HTG Molecular Diagnostics mulls $60M IPO for next-gen profiling technology

HTG Molecular Diagnostics filed plans for a $60 million initial public offering to ramp up development for its next-generation molecular profiling technology and cash in on a growing market.